Research may show why some brain tumors resist treatment
Scientists at MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide.
Simply put, it’s all in their DNA. The discovery could open up new avenues for treating certain kinds of brain cancer.
DNA, the body’s essential storehouse for genetic information, can do marvelous things such as passing on hereditary...
Patrick Hwu is named head of Cancer Medicine
Patrick Hwu, M.D., chair of Melanoma Medical Oncology and Sarcoma Medical Oncology at MD Anderson Cancer Center, has been named division head...
New surgical protocol for ovarian cancer is showing improved survival rates
Triathlete and marathoner Leslie Russell teaches reading to children with dyslexia in the Spring Branch Independent School District. It’s...
Developing a drug to starve cancer cells
The first experimental drug to be produced by MD Anderson’s drug discovery and development institute will kill cancer cells in a new way — by depriving them of the fuel necessary for growth and survival.
Named after MD Anderson’s Institute for Applied Cancer Science (IACS) where it was developed, IACS-10759 blocks the conversion of nutrients into the energy that fuels cancer cells. The drug does this by blocking the function of...
MD Anderson receives $22.3 million in CPRIT research funding
It was announced last month that MD Anderson Cancer Center would be awarded more than $22 million in research grants from the Cancer Prevention...
Study: Lenvatinib improves survival for thyroid cancer patients
In a pivotal Phase III study led by researchers at MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic...
Targeting breast cancer by taking aim at cells that regulate blood flow
Tumors require blood to emerge and spread. That is why MD Anderson Cancer Center scientists believe targeting blood vessel cells known as...
Searching for how melanoma builds resistance to drugs
Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein...
MD Anderson researchers among Journal of Clinical Oncology’s most-cited researchers
Fourteen current and former MD Anderson researchers were represented in 11 of the 50 most-cited Journal of Clinical Oncology (JCO) articles...
Concurrent treatment of HIV and cancer improves survival outcomes
Concurrent HIV and cancer present special challenges in the clinic, regardless of which disease is diagnosed first. The simultaneous treatment...
Former MD Anderson president Mendelsohn ‘Makes History’
John Mendelsohn, M.D., president of MD Anderson from 1996-2011, recently received the Texas State History Museum Foundation’s "History-Making...